Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma reported Q1 2026 revenue of $225,000 from an NIH SBIR grant, with a net loss of $2.3 million and unrestricted cash of $4.7 million. The company completed enrollment in the first cohort of its Phase 1b norovirus challenge study for CDI-988 and received FDA Fast Track designation for the asset.
Key figures
- Revenue
- 225000
- Net loss
- 2299000
- G and a expense
- 1210000
- R and d expense
- 1371000
- Working capital
- 3700000
- Sbir grant total
- 500000
- Shares outstanding
- 13787000
- Sbir grant received
- 225000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.